This profile has not been claimed and data may not be accurate.
19th percentile
Computational drug discovery researcher turned founder targeting drug-resistant breast cancer
Credibility
Domain Expertise · 67th percentile
- OpenAlex h-index of 29 places Ho Leung Ng in the 20–49 tier, reflecting strong academic research credibility in computational chemistry and drug discovery.
- Identified researcher on OpenAlex with an h-index of 29 and 4,878 citations across 94 works in computational drug discovery and structural biology.
Relationship Matrix
Founder score
- 95%Probability of being accurate (95%)GitHub account @holeung is identified as Ho Leung Ng's account, confirmed by name match and LinkedIn URL in the profile bio.
- 95%Probability of being accurate (95%)GitHub account @holeung has been active for approximately 10 years, created on 2015-02-11.
- 90%Probability of being accurate (90%)Current founder of Rise Bio, a computational AI drug discovery company focused on drug-resistant breast cancer.
- 90%Probability of being accurate (90%)GitHub account @holeung is dormant with no public repo push activity detected.
- 80%Probability of being accurate (80%)OpenAlex h-index of 29 places Ho Leung Ng in the 20–49 tier, reflecting strong academic research credibility in computational chemistry and drug discovery.
- 80%Probability of being accurate (80%)Identified researcher on OpenAlex with an h-index of 29 and 4,878 citations across 94 works in computational drug discovery and structural biology.
- 50%Probability of being accurate (50%)Identified Stack Overflow account for Ho Leung Ng with 1 reputation.
- 0%Probability of being accurate (0%)This row intentionally left — no venture raised signal detected; Rise Bio is pre-seed with no disclosed funding.
What you likely need
You're a deep-science founder with serious academic credentials but a pre-seed company that's nearly invisible to the biotech investor community, so your Festival events should prioritize warm introductions to AI-bio seed investors and non-dilutive funding insiders. You also need peer founders who've navigated the scientist-to-CEO transition to help you close the commercialization gap — whether through a co-founder hire or a business-side advisor. Smaller, high-trust dinners and roundtables with Andreessen Bio, 8VC, or Lux-adjacent founders and grant veterans will do more for you right now than any large networking event.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- fundraisingA pre-seed biotech founder dinner with portfolio founders and scouts from Andreessen Horowitz Bio, 8VC, and Lux Capital to pressure-test an AI drug discovery pitch and surface warm intros ahead of a formal seed raise
- introsA Valence Labs and Atomwise alumni roundtable for AI-driven drug discovery founders to trade warm introductions to biotech angels and early-stage biotech fund partners
- fundraisingAn NIH SBIR/STTR office hours session with founders who have successfully closed Phase I grants in computational oncology and breast cancer drug discovery to workshop Rise Bio's application strategy
- hiringA founder dinner for science-led pre-seed biotech CEOs actively recruiting a business-focused co-founder or CBO with biotech commercialization experience to complement a deep technical team
- positioningA small workshop for academic-founder hybrids with h-index credibility converting unpublished research into public-facing preprints, technical blogs, or demo notebooks that signal commercial traction to technical biotech investors
- tacticalA build-in-public demo night for computational biology and AI drug discovery founders publishing open-source tools or Jupyter notebooks to make dormant GitHub profiles visible to technical seed investors
- positioningA happy hour for pre-seed biotech founders without a public-facing website to workshop pipeline pages, technology platform copy, and team bios that convert cold investor curiosity into warm inbound
- wellbeingA dinner for PhD and academic founders navigating the scientist-to-CEO transition at the pre-seed stage, sharing playbooks on credibility-building, investor storytelling, and when to bring on commercial leadership